HUYABIO International
12531 High Bluff Drive
Suite 138
San Diego
California
92130
United States
Website: https://huyabio.com/
About HUYABIO International
HUYABIO has now grown to be the leader in globalizing China’s pharmaceutical innovation. Meeting the challenge of tomorrow’s unmet medical needs requires utilizing the talents of Chinese researchers and helping to move their discoveries forward. Our HUYABIO teams in San Diego, Tokyo, Dublin, Montreal, Seoul and our eight China offices are committed to building relationships that enable candidate compounds to be more accessible internationally. With diverse approaches including in-licensing, alliances, co-development, research funding and creative financial partnerships, HUYABIO is poised to bring China’s healthcare discoveries to benefit the rest of the world.
When joining us at HUYABIO, you become part of the team, right here and now. Where you are empowered to lead and perform at your best. Where you collaborate across disciplines, borders, and continents. HUYABIO International is committed to creating a diverse environment and is proud to be an equal opportunity employer.
86 articles about HUYABIO International
-
HUYA Bioscience International Announces Orphan Drug Designation for HBI-8000 Monotherapy Adult T-cell Leukemia-Lymphoma ATL in Japan
9/28/2020
HUYA Bioscience International (HUYABIOTM), the leader in accelerating global development of China's pharmaceutical innovations, announced today the Ministry of Health, Labour and Welfare (MHLW) granted HBI-8000 orphan drug designation (ODD) in Japan as monotherapy for relapsed or refractory Adult T-cell Leukemia-Lymphoma or (ATL).
-
HUYA Bioscience International Licenses the Novel SHP2 Inhibitor HBI-2376 for Development in Oncology
8/4/2020
HUYA Bioscience International (HUYABIO ® ), the leader in accelerating global development of China's pharmaceutical innovations, announced today it has exclusively licensed worldwide rights, outside of China , to the SHP2 inhibitor, HBI-2376, from Suzhou GenHouse. SHP2 is an import
-
HUYA Bioscience International® Announces the Successful Completion of Phase 1 Trial of HBI-3000
2/28/2020
HUYA Bioscience International, the leader in accelerating global development of China's pharmaceutical innovations, has presented the results of a Phase I study of HBI-3000, a novel drug for cardioversion of atrial fibrillation (AF).
-
HUYA Bioscience International Appoints Meiji Seika Pharma as Exclusive Distributor For HBI-8000 in Japan and Other Asian Countries
1/8/2020
HUYA Bioscience International CEO & Executive Chair, Dr. Mireille Gillings announced the appointment of Meiji Seika Pharma as an exclusive distributor for its lymphoma product, HBI-8000, in Japan.
-
HUYA Bioscience International expanded oncology pipeline includes combination with checkpoint inhibitor for solid tumors
6/4/2018
HUYA Bioscience International (HUYA) announced it is at a key stage in the company's development of HBI-8000, HUYA's lead novel epigenetic drug with important immunomodulatory properties.
-
HUYA Bioscience Establishes Strategic Partnership With Suzhou BioTOP
7/10/2017
-
HUYA Bioscience Release: Biopharma And CAS Innovation And Investment Company Establish Strategic Collaboration
1/18/2017
-
HUYA Bioscience's Dr. Mireille Gillings Named Pharma Executive Of The Year At The Biopharma Industry Awards 2016
3/24/2016
-
HUYA Bioscience Adds To Executive Team
3/23/2016
-
HUYA Bioscience Celebrates 10 Years In China
3/22/2016
-
HUYA Bioscience Acquires Exclusive Rights To Immuno-Oncology Products From Fudan University
3/15/2016
-
HUYA Bioscience Expands Senior Management Team
3/3/2016
-
Eisai Company Buys Cancer Drug Rights From HUYA Bioscience in $280 Million+ Deal
2/1/2016
-
HUYA Bioscience International Adds To Senior Management Team
12/23/2015
-
HUYA Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan
12/22/2015
-
HUYA Bioscience International Expands Senior Management Team
12/15/2015
-
HUYA Bioscience International Expands Senior Management Team
12/10/2015
-
HUYA Bioscience International Sponsors 'Best New Drug' Category At SCRIP Awards
12/3/2015
-
HUYA Bioscience International Expands Into South Korea
12/2/2015
-
HUYA Bioscience International Announces A Strategic Alliance With The Korea Drug Development Fund
11/30/2015